Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30630019 | 1.00 | LMNA (0.53) | LMNATDP1TP53ALDH1A1POLB | |
| SCHEMBL31671417 | 1.00 | LMNA (0.53) | LMNATDP1TP53ALDH1A1POLB | |
| SCHEMBL13669517 | 1.00 | LMNA (0.53) | LMNATDP1TP53ALDH1A1POLB | |
| SCHEMBL16601680 | 0.85 | LMNA (0.41) | LMNATDP1ALDH1A1POLBL3MBTL1 | |
| SCHEMBL10262386 | 0.85 | LMNA (0.54) | LMNATDP1ALDH1A1POLBHTT | |
| SCHEMBL14928969 | 0.83 | TDP1 (0.51) | LMNATDP1TP53ALDH1A1POLB | |
| SCHEMBL14928346 | 0.83 | TDP1 (0.51) | LMNATDP1TP53ALDH1A1POLB | |
| SCHEMBL30629992 | 0.83 | TDP1 (0.45) | LMNATDP1TP53ALDH1A1POLB | |
| SCHEMBL26115282 | 0.83 | TDP1 (0.45) | LMNATDP1TP53ALDH1A1POLB | |
| SCHEMBL30629983 | 0.83 | TDP1 (0.45) | LMNATDP1TP53ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504179-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | Corbus Pharmaceuticals, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196556-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196556-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-8426645-B2 | Process for production of optically active fluoroamine | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-04-23 | — | — | US | disclosed |
| US-8058412-B2 | Dehydroxyfluorination agent | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20110034732-A1 | Process for Production of Optically Active Fluoroamine | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034732-A1 | Process for Production of Optically Active Fluoroamine | PHF2, HNMT, PHF8 | LMNA 3670/4885TDP1 4348/4885TP53 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.